OakChart

Odyssey Therapeutics Inc

ODTXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:37 PM ET

20.47+0.47 (2.36%)
2026-11-11 19:37 CET
Market cap
961.36 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-53.06 USD m
Free cash flow, TTM
-42.05 USD m
EPS diluted, TTM
-1.11
P/E
-
Compare

Price

ODTX against its 20 and 50-day averages
2050beatmiss
15.0020.0025.001.6M3.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ODTXclose 20.4720-day 19.2850-day 20.9020.4752w high52w low

29.5% under the 52-week high of 29.05 on 4 Sep 2026. 52-week low 15.10 on 8 Jul 2026. Last 15 sessions, 24.2% high to low

Profile

ODTX
52-week range, 38% of the way up
15.1029.05

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

IndexRUT
IPOMay 08, 2026
ATR, 14d1.73
Rel volume0.52
Short float17.04%
Insider own59.13%
Inst own32.51%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap984.07M
Enterprise Value681.55M
Income-151.97M
Sales4.73M
Book/sh7.84
Cash/sh6.78
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOMay 08, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S208.05
P/B2.61
P/C3.02
P/FCF-
EV/EBITDA-
EV/Sales144.09
Quick Ratio12.94
Current Ratio12.94
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.18
EPS next Y-4.44
EPS next Q-1.09
EPS this Y-13.86%
EPS next Y24.42%
EPS next 5Y6.00%
EPS past 3/5Y-6.04% -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-28.92%
Sales Q/Q-100.00%
EarningsNov 04 BMO
EPS/Sales Surpr.-2.54% -

Ownership

Insider Own59.13%
Insider Trans17.25%
Inst Own32.51%
Inst Trans70.08%
ROA-
ROE-
ROIC-38.37%
Gross Margin-6.68%
Oper. Margin-3398.82%
Profit Margin-3212.18%
SMA206.20%
SMA50-2.06%
SMA2003.82%
Trades-

Technical

Shs Outstand47.94M
Shs Float19.65M
Short Float17.04%
Short Ratio11.24
Short Interest3.35M
52W High29.05 -29.53%
52W Low15.10 35.58%
Volatility10.89% 8.86%
ATR (14)1.73
RSI (14)54.24
Beta-
Rel Volume0.52
Avg Volume297.82K
Volume100,252

Performance

Perf Week4.99%
Perf Month18.75%
Perf Quarter-1.19%
Perf Half Y14.12%
Perf YTD2.36%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.12
Target Price34.67
Prev Close20.00
Price20.47
Change %2.36%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Nov 06, 2026ResumedHH.C. WainwrightBuy$40+95.4%
Oct 12, 2026InitiatedUUBSBuy$27+31.9%
Oct 09, 2026InitiatedRRaymond JamesOutperform$42+105.2%
Aug 27, 2026InitiatedHH.C. WainwrightBuy$44+114.9%
Jun 02, 2026InitiatedWWedbushOutperform$30+46.5%
Jun 02, 2026InitiatedTTD CowenBuy
Jun 02, 2026InitiatedOOppenheimerOutperform$40+95.4%
Jun 02, 2026InitiatedJJP MorganOverweight$26+27.0%
Jun 02, 2026InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
ALMSAlumis Inc888.99M
ABVXAbivax ADR8.04B
ZBIOZenas Biopharma Inc1.95B
ATTOAttovia Therapeutics Inc791.06M
JBIOJade Biosciences Inc1.08B
MLTXMoonLake Immunotherapeutics1.17B
SYRESpyre Therapeutics Inc10.06B
ANABAnaptysBio Inc1.45B
ORKAOruka Therapeutics Inc7.30B
EVMNEvommune Inc315.20M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
TPG GP A, LLCFormer 10% OwnerMay 11 '26Buy18.001,388,88925,000,0023,690,146May 13 05:10 PM
Dimension Capital II, L.P.DirectorMay 08 '26Buy18.001,111,11119,999,9983,333,516May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerMay 11 '26Buy18.00555,5559,999,9901,831,383May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerMay 11 '26Sale18.001,78032,040440,981May 11 09:11 PM
LEIDEN JEFFREY MDirectorMay 08 '26Buy20.005,000100,000270,198May 11 08:35 PM
Haas JasonChief Financial OfficerMay 08 '26Buy20.001,00020,00062,908May 11 08:32 PM
Li Nan (LN)DirectorMay 11 '26Buy18.001,111,11119,999,9983,333,516May 11 08:30 PM
Chu ShelleyDirectorMay 11 '26Buy18.0011,111199,99811,111May 11 08:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.100-1.073-1.1050.000.008
2026Q22026-09-02-1.612-1.612-1.1020.000.006
2026Q12026-06-17-6.770-1.114-0.7970.000.004
2026Q4---1.092--0.008
2027Q1---1.182--0.006
2027Q2---1.223--0.006
2027Q3---1.238--0.006
2027Q4---1.202--0.006
2028Q1---1.005---1
2028Q2---1.026---1
2028Q3---1.048---1
2028Q4---1.095---1
2029Q1---1.188---1
2029Q2---1.289---1
2029Q3---1.221---1
2029Q4---1.226---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-21.402-42.600-19.7502.992.98
2026FY--5.875--0.00
2027FY--4.440--0.00
2028FY--4.286--0.00
2029FY--5.073--0.00
2030FY--5.214--0.40

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-046000.000.000.00
2026Q4S2026-11-036000.000.000.00
2026Q4S2026-10-095000.000.000.00
2026Q4S2026-09-264000.000.000.00
2026Q4S2026-09-025000.000.000.00
2026Q4S2026-08-265000.000.000.00
2026Q4S2026-06-184000.000.000.00
2026Q4S2026-06-014000.000.000.00
2026Q4S2026-02-251000.000.000.00
2026Q4S2026-01-061000.000.000.00
2026Q4R2026-11-04513-1.07-1.11-1.01
2026Q4R2026-11-03513-1.07-1.11-1.01
2026Q4R2026-10-24500-1.07-1.44-0.90
2026Q4R2026-10-20510-1.07-1.44-0.90

Estimate history

EPS, annual-2.643-2.775-2.764-3.151-3.1779
Period2022202320242025TTM
EPS, quarterly-0.717-0.781-0.8-0.859-0.738-0.797-1.102-1.107
PeriodQ4 '23Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual01.0374.4722.9764.73
Period2022202320242025TTM
Sales, quarterly0.2871.7551.9180.9590.099000
PeriodQ4 '23Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual47.17447.17447.17447.17447.941
Period2022202320242025MRQ
Shares, quarterly47.17447.17448.03148.03148.03148.03147.89147.941
PeriodQ4 '23Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.002.984.471.040.00
Cost of Goods Sold Incl. D&A1.014.915.194.912.76
Gross Profit-1.01-1.94-0.72-3.87-2.76
Selling, General and Administrative Excl. Other52.35159.22134.50129.57120.01
Research and Development42.12126.62112.58112.28101.75
Other Operating Expense0.000.000.000.000.00
Operating Income-53.36-161.16-135.22-133.44-122.78
Interest Expense0.010.020.020.340.29
Unusual Expense3.31-4.051.800.305.13
Net Income Before Taxes-53.01-149.57-128.85-125.49-124.32
Income Taxes0.05-0.930.470.450.35
Consolidated Net Income-53.06-148.65-129.32-125.94-124.67
Net Income From Continuing Operations-53.06-148.65-129.32-125.94-124.67
Net Income-53.06-148.65-130.40-130.92-124.67
EPS (Recurring)-1.06-3.21-2.74-2.77-2.57
EPS (Basic, Before Extraordinaries)-1.11-3.15-2.76-2.78-2.64
EPS (Diluted)-1.11-3.15-2.76-2.78-2.64
EBITDA-52.35-156.25-130.03-128.53-120.01
Non-Operating Income (Expense)3.677.558.198.583.88
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense6.2711.316.864.954.36
Gross Margin-6.68-65.02-16.12-373.29-
Operating Margin-3,398.82-5,415.19-3,023.77-12,867.79-
Net Margin-3,212.18-4,994.86-2,915.94-12,624.88-
Shares Outstanding47.9447.1747.1747.1747.17
Market Capitalization961.36961.36---

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q12024Q42023Q4
Total Revenue0.000.000.000.100.961.921.750.29
Cost of Goods Sold Incl. D&A1.011.041.171.191.271.301.291.23
Gross Profit-1.01-1.04-1.17-1.09-0.310.620.46-0.94
Selling, General and Administrative Excl. Other52.3545.6938.5035.2942.1845.4337.5829.88
Research and Development42.1236.2332.3226.3230.2338.7731.4825.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-53.36-46.74-39.67-36.38-42.49-44.81-37.12-30.82
Interest Expense0.010.020.010.000.000.000.000.01
Unusual Expense3.318.730.111.87-0.57-5.650.380.37
Net Income Before Taxes-53.01-52.80-38.20-35.52-41.20-38.30-35.88-28.76
Income Taxes0.05-0.010.06-0.060.030.140.050.10
Consolidated Net Income-53.06-52.79-38.26-35.46-41.23-38.44-35.93-28.86
Net Income From Continuing Operations-53.06-52.79-38.26-35.46-41.23-38.44-35.93-28.86
Net Income-53.06-52.79-38.26-35.46-41.23-38.44-36.84-33.84
EPS (Recurring)-1.06-0.97-0.80-0.71-0.87-0.88-0.78-0.71
EPS (Basic, Before Extraordinaries)-1.11-1.10-0.80-0.74-0.86-0.80-0.78-0.72
EPS (Diluted)-1.11-1.10-0.80-0.74-0.86-0.80-0.78-0.72
EBITDA-52.35-45.69-38.50-35.19-41.22-43.51-35.83-29.59
Non-Operating Income (Expense)3.672.691.592.740.720.871.622.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.274.482.043.872.922.362.101.55
Gross Margin----1,100.00-32.1232.2726.32-329.27
Operating Margin----36,749.49-4,430.34-2,336.18-2,115.16-10,739.72
Net Margin----35,820.20-4,299.79-2,003.91-2,098.92-11,790.94
Shares Outstanding47.9447.8948.0348.0348.0348.0347.1747.17
Market Capitalization961.36898.67907.31-----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments181.36129.35187.00241.04
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets9.306.165.547.67
Total Current Assets190.66135.51192.54248.71
Net Property, Plant & Equipment26.0139.4746.7352.77
Total Investments and Advances38.413.2132.560.50
Intangible Assets14.5913.9214.4614.06
Deferred Tax Assets5.108.509.33-
Other Assets0.125.330.231.11
Total Assets274.89205.94295.85317.15
Short Term Debt Incl. Current Port. of LT Debt5.214.583.861.72
Accounts Payable7.876.327.738.05
Income Tax Payable-0.17--
Other Current Liabilities13.3917.3510.5013.02
Total Current Liabilities26.4828.4122.0922.80
Long Term Debt21.9026.4330.5239.14
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities5.108.509.33-
Other Liabilities6.1310.228.418.20
Total Liabilities59.6173.5770.3570.14
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value703.56514.89488.20391.63
Common Equity-488.28-382.53-262.71-144.62
Total Shareholders Equity215.28132.37225.50247.01
Accumulated Minority Interest0.000.000.000.00
Total Equity215.28132.37225.50247.01
Total Liabilities & Stockholders Equity274.89205.94295.85317.15
Book Value Per Share-10.35-8.11-5.57-3.07
Tangible Book Value Per Share-10.66-8.40-5.88-3.36
Price to Book Ratio2.55---
Return on Assets-61.83-51.54-41.09-
Return on Equity-85.52-72.27-53.31-
Return on Invested Capital-62.67-81.44-49.19-43.57
Quick Ratio7.204.778.7210.91
Current Ratio7.204.778.7210.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-53.06-148.65-129.32-125.94-124.67
Depreciation1.014.915.194.912.76
Other Funds (Non Cash)12.4919.009.967.4122.60
Funds from Operations-39.56-124.74-114.16-113.62-99.30
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-1.98-4.73-3.310.90-0.54
Cash from Operating Activities-41.54-129.47-117.47-112.73-99.84
Capital Expenditures-0.50-1.23-0.76-5.06-13.03
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.360.000.020.00
Purchase or Sale of Investments43.77-103.0797.55-159.990.00
Purchase of Investments0.00-208.97-52.61-238.110.00
Sale Or Maturity of Investments43.77105.90150.1678.120.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities43.29-103.9496.78-165.02-13.03
Cash Dividends Paid0.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00--0.00
Change in Capital Stock-3.13215.6527.9996.83177.84
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock-3.13215.6527.9996.83177.84
Proceedsfrom Stock Options-3.28212.4627.4896.57177.76
Issuance or Reduction of Debt, Net-0.050.000.00-4.764.88
Change in Long Term Debt-0.050.000.00-4.764.88
Issuance of Long Term Debt0.000.000.000.004.88
Reduction of Long Term Debt-0.050.000.00-4.760.00
Net Financing Active Other Cash Flow0.000.00-1.010.000.00
Other Financing Activities Uses0.000.00-1.010.000.00
Cash from Financing Activities-3.18215.6526.9892.08182.72
Exchange Rate Effect0.040.320.050.01-0.02
Net Change in Cash-1.39-17.456.34-185.6769.83
Free Cash Flow-42.05-130.70-118.23-117.78-112.87
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments326.00310.57175.75---
Short Term Receivables0.000.000.00---
Inventories0.000.000.00---
Other Current Assets11.8010.899.35---
Total Current Assets337.80321.46185.10---
Net Property, Plant & Equipment20.7621.9224.48---
Total Investments and Advances64.20125.953.45---
Intangible Assets14.1214.1914.23---
Other Assets1.220.341.81---
Total Assets438.10483.85229.07---
Short Term Debt Incl. Current Port. of LT Debt5.535.465.37---
Accounts Payable8.267.678.22---
Other Current Liabilities12.3115.168.62---
Total Current Liabilities26.1028.3022.21---
Long Term Debt17.9519.36724.31---
Provision for Risks Charges0.000.000.00---
Other Liabilities18.2814.976.24---
Total Liabilities62.3362.63752.76---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.000.000.00---
Common Equity375.77421.22-523.69---
Total Shareholders Equity375.77421.22-523.69---
Accumulated Minority Interest0.000.000.00---
Total Equity375.77421.22-523.69---
Total Liabilities & Stockholders Equity438.10483.85229.07---
Book Value Per Share7.848.80-10.90---
Tangible Book Value Per Share7.548.50-11.20---
Price to Book Ratio2.55-1.72-1.73---
Return on Invested Capital-13.48-11.98-19.07---
Quick Ratio12.9411.368.33---
Current Ratio12.9411.368.33---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-53.06-52.79-38.26-35.46-41.23-38.44
Depreciation1.011.041.171.191.271.30
Other Funds (Non Cash)12.4916.063.258.203.293.80
Funds from Operations-39.56-35.68-33.84-26.08-36.68-33.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.981.17-7.19-5.182.42-5.28
Cash from Operating Activities-41.54-34.51-41.03-31.26-34.26-38.62
Capital Expenditures-0.50-0.19-0.15-0.05-0.03-0.93
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.280.000.220.080.05
Purchase or Sale of Investments43.77-211.5434.95-173.0723.2535.00
Purchase of Investments0.00-246.490.00-185.770.000.00
Sale Or Maturity of Investments43.7734.9534.9512.7023.2535.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities43.29-211.4434.80-172.9023.3034.13
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-3.13292.060.6590.82118.760.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-3.13292.060.6590.82118.760.23
Proceedsfrom Stock Options-3.28291.480.0090.73118.750.00
Issuance or Reduction of Debt, Net-0.05-0.05-0.02-0.04-0.04-0.04
Change in Long Term Debt-0.05-0.05-0.02-0.04-0.04-0.04
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.05-0.05-0.02-0.04-0.04-0.04
Net Financing Active Other Cash Flow0.000.14-0.140.000.000.00
Other Financing Activities Uses0.000.14-0.140.000.000.00
Cash from Financing Activities-3.18292.160.4890.78118.720.20
Exchange Rate Effect0.040.100.02-0.100.320.07
Net Change in Cash-1.3946.31-5.72-113.48108.09-4.22
Free Cash Flow-42.05-34.69-41.18-31.30-34.29-39.55

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.04%3.3M19.7M260.61K
2026-10-1516.71%3.3M19.6M264.57K
2026-09-3015.81%3.1M19.6M270.88K
2026-09-1511.25%2.2M19.6M255.53K
2026-08-3111.25%2.2M19.6M268.48K
2026-08-1411.46%2.2M19.6M298.63K
2026-07-318.45%2.3M26.9M379.98K
2026-07-156.92%2.0M28.8M417.02K
2026-06-306.31%1.8M28.5M446.73K
2026-06-154.72%1.3M28.5M429.33K
2026-05-292.98%0.5M17.3M533.10K
2026-05-150.46%0.1M18.6M807.94K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-09-098-KCurrent report2026-09-08SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-1710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-06-05SCHEDULE 13GSEC
2026-05-18SCHEDULE 13GSEC
2026-05-18SCHEDULE 13DSEC
2026-05-18SCHEDULE 13DSEC
2026-05-15SCHEDULE 13DSEC
2026-05-15SCHEDULE 13DSEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-08SEC
2026-05-123Initial statement of beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-08SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0575.32M732.04K1
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC12.98%
SR ONE CAPITAL MANAGEMENT, LP7.90%
TPG GP A, LLC7.68%
Lightspeed Management Company, L.L.C.7.51%
ORBIMED ADVISORS LLC6.25%
Sanofi4.14%
DEERFIELD MANAGEMENT COMPANY, L.P.2.18%
Sands Capital Alternatives, LLC1.82%
HHLR ADVISORS, LTD.1.73%
General Catalyst Group Management, LLC1.69%

Funds

Fund% owned
Fidelity Growth Company Fund2.30%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.11%
Select Biotechnology Portfolio0.71%
Fidelity Growth Company K6 Fund0.69%
Fidelity Series Growth Company Fund0.57%
T. Rowe Price Health Sciences Fund, Inc.0.38%
VANGUARD EXTENDED MARKET INDEX FUND0.37%
Franklin Biotechnology Discovery Fund0.21%
Fidelity Extended Market Index Fund0.16%
Schwab U.S. Small-Cap ETF0.15%

OakChart. ODTX. Cached 15 minutes.

Some panels did not load: news.